Immunic (IMUX) to Release Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) is expected to be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Immunic Price Performance

NASDAQ:IMUX opened at $1.05 on Thursday. The firm has a market cap of $94.58 million, a price-to-earnings ratio of -0.85 and a beta of 1.87. The firm’s fifty day moving average price is $1.02 and its 200 day moving average price is $1.26. Immunic has a 1-year low of $0.92 and a 1-year high of $2.11.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. D. Boral Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Tuesday, January 7th. StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Monday, February 10th. Finally, HC Wainwright started coverage on Immunic in a research note on Monday, November 25th. They issued a “buy” rating and a $10.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $12.67.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.